Fall 9-1-2001

PHAR 553.01: Therapeutics III

Michael P. Rivey
University of Montana, Missoula

Follow this and additional works at: https://scholarworks.umt.edu/syllabi
Let us know how access to this document benefits you.

Recommended Citation
Rivey, Michael P., "PHAR 553.01: Therapeutics III" (2001). Syllabi. 6206.
https://scholarworks.umt.edu/syllabi/6206

This Syllabus is brought to you for free and open access by the Course Syllabi at ScholarWorks at University of Montana. It has been accepted for inclusion in Syllabi by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact scholarworks@mso.umt.edu.
Pharmacy 553 Pharm.D.: Therapeutics III Fall 2001

Lectures: M-W-F 1110-1200 Skaggs Bldg Rm 117
F only 1010-1100 “ Rm 114

Course Coordinator: Michael Rivey ===> M. Rivey
Instructors: Douglas Allington Office: 243-6796
Rose Macklin Community Hosp: 327-4299 ext. 7605
Cathy Bartels
Sarah Miller Pager: 329-6122
Gayle Cochran Home: 251-3369
Donna Beall
Lee Ann Bradley

Material and Resources
APhA: Handbook of Nonprescription Drugs
Medical Letter on Drugs & Therapeutics
Goodman & Gilman's Pharmacological Basis of Therapeutics
Boh Pharmacy Practice Manual
A medical dictionary

Optional Texts: Murphy: Clinical Pharmacokinetics pocket reference
Evans: Applied Pharmacokinetics
Young, Koda-Kimble: Applied Therapeutics
Herfindal, Gourley, Hart: Clinical Pharmacy and Therapeutics
Hansten & Horn: Drug Interactions
Pagana & Pagana: Diagnostic & Lab Test Ref., or other lab. text

Goals of the Course

To promote the students' understanding of common disease states with particular emphasis on the facets of diseases that are amenable to drug therapy.

To familiarize the student with the proper use of drugs in a clinical setting.

To develop the students' awareness of factors that should be considered prior to selection of a drug and the appropriate parameters that should be monitored for therapeutic as well as undesired effects.

To encourage the students' ability to problem-solve in the clinical setting.
Performance Objectives
Upon completion of this course, each student shall be able to:

Relate the pathophysiology of a disease to the known or purported action of a drug.

Evaluate the seriousness of a disorder based on the signs and symptoms related to a diagnosed problem, and:
--determine the necessity of drug therapy,
--when applicable, choose the proper drug and/or drug product for the situation.

Determine the place of non-pharmacologic and natural therapies, when applicable.

Tailor the drug therapy of an individual based on patient characteristics and known pharmacokinetics principles.

Identify potential drug-drug interactions.

Monitor the appropriate parameters of a disease to determine if the patient is responding positively to therapy.

Monitor for adverse drug reactions and exacerbations of underlying patient problems resulting from drug therapy.

Student Responsibilities and Obligations
* To attend and participate in lecture sessions.
* To do assigned readings from the texts.
* To attend Integrated Studies conferences, prepare each case in advance, to present a patient case, and participate in the discussion of all patient presentations.
* To perform satisfactorily on course quizzes and lecture examinations.
GRADING IN COURSE: Phar 553 Therapeutics III

3 midterm exams: 100 points each 300 points
Final exam (comprehensive, multiple choice) 130 points
(100 pts comprehensive, 30 pts over last 6 lectures)
Topic quizzes: 8 quizzes graded on 10 pts each Bonus pts > 75%
TOTAL POINTS FOR COURSE 430 POINTS

Class quizzes: The purposes of the quizzes are to promote reading of the text before a topic and encourage class attendance and attention. Quizzes will occur before topic lectures and will test understanding of basic concepts in the reading assignment, and will cover only chapter/reading material associated with the day the quiz is scheduled. A quiz will consist of 5 multiple choice or true/false questions, each worth 2 points. QUIZ on syllabus indicates a quiz will be given for assigned reading at start of the given lecture. Lowest 2 quiz grades will be thrown out; no make-ups will be allowed for quiz. Scoring: Quiz performance can only benefit student; bonus points for the course will be awarded for all points over 75% (i.e. 60 pts) of the potential total 80 pts on the quizzes (10 total quizzes – 2 throw-outs = 8x10 pts)

NOTE: Reading assignments are from DiPiro (4th edition) & APhA books

Integrated Studies Conferences: you will be assigned to a conference based on period you registered for; instructors are not necessarily the ones under which you registered. Attendance/make-up is required for all topics/cases; you may attend a different conference in order to complete the assignment, but ONLY with instructor permission. The “make-up” requirement for a conference missed due to unavoidable incident will be at the discretion of the instructor, dependent on the topic. Failure to complete any conference will result in a grade of “fail” for course.

Exams:
3 midterm exams: Tests will be in "traditional" case report fashion with short answers required. Tests will be given during a “common” time period. B.S. and Pharm.D. classes will take tests simultaneously.
Final exam: 65 multiple choice questions worth 2 pts each. Effort will be made to design questions in the style similar to the NAPLEX exam.

Class civility: Your student colleagues have strongly indicated to us that they wish to spend their valuable time in class listening to therapeutics topics. They do not appreciate any “side” conversations while the instructor is lecturing. They do appreciate students raising questions about important lecture aspects for further discussion or clarification.

Out of respect for your classmates, we will not tolerate excessive and disruptive talking during lecture. The instructor may first ask you to be silent; you may be asked to leave class if you persist in disruptive talking. The instructor will be the judge of “what” constitutes disruption. Please note that we encourage questions and relevant discussion.
<table>
<thead>
<tr>
<th>Date</th>
<th>Reading</th>
<th>Instructor</th>
<th>Reading</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5W</td>
<td>Introduction/ Liver disease</td>
<td>MPR</td>
<td></td>
</tr>
<tr>
<td>7F*</td>
<td>Renal disease/ <strong>joint</strong>/ QUIZ</td>
<td>DRA</td>
<td>40</td>
</tr>
<tr>
<td>7F</td>
<td>Liver disease</td>
<td>MPR</td>
<td>38</td>
</tr>
<tr>
<td>10M</td>
<td>Liver Disease</td>
<td>MPR</td>
<td>35</td>
</tr>
<tr>
<td>12W</td>
<td>Renal disease</td>
<td>DRA</td>
<td>41</td>
</tr>
<tr>
<td>14F*</td>
<td>Pain Management/ <strong>joint</strong></td>
<td>LAB</td>
<td>56</td>
</tr>
<tr>
<td>14F</td>
<td>Renal disease</td>
<td>DRA</td>
<td>42</td>
</tr>
<tr>
<td>17M</td>
<td>Pain mgmt/ <strong>joint</strong></td>
<td>LAB</td>
<td></td>
</tr>
<tr>
<td>19W</td>
<td>Headache/ <strong>joint</strong>/ QUIZ</td>
<td>DB</td>
<td>57</td>
</tr>
<tr>
<td>21F*</td>
<td>Headache/ <strong>joint</strong></td>
<td>DB</td>
<td>OTC 3</td>
</tr>
<tr>
<td>21F</td>
<td>Nausea &amp; vomiting</td>
<td>LAB</td>
<td>33, OTC 5</td>
</tr>
<tr>
<td>24M</td>
<td>N&amp;V, emetics</td>
<td>LAB</td>
<td>OTC 25</td>
</tr>
<tr>
<td>25T</td>
<td>Career Fair</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26W</td>
<td>Oncology</td>
<td>CLB</td>
<td>DiPiro pp. 1957-71</td>
</tr>
<tr>
<td>28F*</td>
<td>Oncology</td>
<td>CLB</td>
<td>pp. 2002-7</td>
</tr>
<tr>
<td>28F</td>
<td>Oncology</td>
<td>CLB</td>
<td>pp. 2013-41</td>
</tr>
<tr>
<td>Oct</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1M</td>
<td>Oncology</td>
<td>CLB</td>
<td>pp. 2046-57</td>
</tr>
<tr>
<td>3W</td>
<td>Arthritis / <strong>joint</strong>/ QUIZ</td>
<td>MPR</td>
<td>84</td>
</tr>
<tr>
<td>5F*</td>
<td>Arthritis</td>
<td>MPR</td>
<td>83</td>
</tr>
<tr>
<td>5F</td>
<td>Arthritis/ <strong>joint</strong></td>
<td>MPR</td>
<td>OTC pp71-74, OTC 5</td>
</tr>
<tr>
<td>5F</td>
<td><strong>Test 1 at 1-3 PM in SB ; through Oncology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8M</td>
<td>Gout/ <strong>joint</strong></td>
<td>MPR</td>
<td>85</td>
</tr>
<tr>
<td>10W</td>
<td>Systemic Lupus Erythematosus</td>
<td>LRM</td>
<td>80</td>
</tr>
<tr>
<td>12F*</td>
<td>Contraception/ <strong>joint</strong>/ QUIZ</td>
<td>DB</td>
<td>OTC 8</td>
</tr>
<tr>
<td>12F</td>
<td>Contraception</td>
<td>DB</td>
<td>76</td>
</tr>
<tr>
<td>15M</td>
<td>Contraception</td>
<td>DB</td>
<td></td>
</tr>
<tr>
<td>17W</td>
<td>Urinary disorders</td>
<td>DRA</td>
<td>OTC 44</td>
</tr>
<tr>
<td>19F*</td>
<td><strong>off, in lieu of test 1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19F</td>
<td><strong>off, in lieu of test 2 ASP-MRM in Seattle</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22M</td>
<td>Menopause/ <strong>joint</strong>/ QUIZ</td>
<td>GAC</td>
<td>78</td>
</tr>
<tr>
<td>24W</td>
<td>Menopause/ <strong>joint</strong></td>
<td>GAC</td>
<td></td>
</tr>
<tr>
<td>26F*</td>
<td>Osteoporosis/ <strong>joint</strong></td>
<td>GAC</td>
<td>82, OTC 419-20</td>
</tr>
<tr>
<td>26F</td>
<td><strong>off, in lieu of test 3</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
553-Ther III, continued

Oct 29M Osteoporosis/ \textbf{joint}\ GAC
31W Obstruct. Airways Dx/ \textbf{joint}/ QUIZ DRA 24

Nov 2F* OAD/ \textbf{joint}\ DRA 25, OTC 10
2F Theophylline kinetics DRA
2F \textbf{Test 2 at 1-3PM in SB114; through osteoporosis}

5M Theophylline PK/respiratory equip DRA
7W Thromboembolic disease/ \textbf{joint}\ MPR 17
9F* Stroke/ \textbf{joint}/ QUIZ MPR 18
9F TED MPR

12M \textbf{Veterans Day}
14W Peripheral Vascular Disease MPR 20
16F* Fluid & electrolytes/ \textbf{QUIZ}\ SJM DiPiro pp. 890-902
16F F & E SJM pp. 902-16

19M F & E SJM
21W OFF; TRAVEL DAY
22Th \textbf{THANKSGIVING HOLIDAY}
23F “ “

26M Nutrition support SJM 128
28W Nutrition support SJM 129
30F* Nutrition support SJM
30F Nutrition support SJM

Dec 3M Diabetes mellitus/ \textbf{QUIZ}\ LRM 70
5W DM LRM
7F* DM LRM
7F DM LRM
7F \textbf{test 3 at 1-3 PM in SB 114; through nutrition support}

10M DM diet/tests LRM OTC 39
12W CLASS EVAL/ Thyroid dx/\textbf{QUIZ}\ MPR 71
14F* Thyroid disorders/ MPR
14F Thyroid dx MPR

Final: \textbf{test 4, 130 pts comprehensive multiple choice NAPLEX/PSAP format}

\textbf{Merged classes}: for certain classes, B.S. students will merge with the P.D. students, denoted as "\textbf{joint}"- this does not affect P.D. time or location of class.
Integrated Studies Phar 571

Monday 0910-1100 SB 111 Macklin
Monday 0910-1100 SB 215 Allington
Wednesday 0910-1100 SB 215 Rivey
Wednesday 0910-1100 SB 335 Allington
Wednesday 0910-1100 SB 337 Macklin

I. Conference topics

week of:
September

3M No conference
10M Liver disease case
17M Renal Disease case
24M Headache/pain management

October

1M J-club for ½ of class; service learning project worksession
8M Arthritis case
15M OTC cases
22M Contraception
29M service learning update: J-club for other ½ of class

November

5M SEMINARS
12M OAD case
19M off week- holiday week
26M TED case

December

3M OTC cases
11M Evaluation/Diabetes case

Seminar: A required activity in the course, graded on a pass/no-pass basis. Student must repeat a no-pass seminar to successfully pass course.